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ORIGINAL ARTICLE

Breast
Cortiva Versus AlloDerm Ready-to-use in Prepectoral
and Submuscular Breast Reconstruction:
Prospective Randomized Clinical Trial Study Design
and Early Findings
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Rajiv P. Parikh, MD, MPHS*†
Marissa M. Tenenbaum, MD*
Yan Yan, MD, MA, MHS, PhD†
Terence M. Myckatyn,
MD, FRCSC, FACS*

Background: Several acellular dermal matrices (ADMs) can be used to provide softtissue support for post- and prepectoral prosthetic breast reconstructions. Yet, several
recent meta-analysis suggest that due to a lack of rigorous evaluation in the setting of
head-to-head prospective randomized control trials, few reliable conclusions regarding
performance outcomes can be drawn. We compare Cortiva 1 mm to AlloDerm RTU in
the setting of submuscular reconstruction in one study, and prepectoral in the second.
Moreover, we present the findings from the interim analysis in our submuscular study.
Methods: Using a single-blinded prospective randomized control trial design, we
compare outcomes in 180 patients undergoing submuscular breast reconstruction
with 16 × 8 cm ADM support (either Cortiva 1 mm or AlloDerm RTU). A parallel
study evaluates 16 × 20 cm sheets of these ADMs in 180 patients undergoing prepectoral reconstructions. Time to drain removal, complications, fill volumes, patientreported outcomes, and narcotic consumption are prospectively evaluated.
Results: Interim analysis of 59 breasts in the submuscular study arm (Cortiva n =
31; AlloDerm n = 28) revealed no statistically significant differences with respect
to outcome. At the time of interim analysis, the AlloDerm RTU group contained
a higher proportion of never-smokers (P = 0.009), while patients implanted with
Cortiva 1 mm received a larger tissue expander (P = 0.02).
Conclusion: We present a protocol for a robust randomized control trial to evaluate outcomes in both submuscular and prepectoral prosthetic breast reconstruction assisted by 2 distinct types of ADM. Our interim analysis reveals no evidence
of inferiority of outcomes in a comparison of AlloDerm to Cortiva. (Plast Reconstr Surg Glob Open 2018;6:e2013; doi: 10.1097/GOX.0000000000002013; Published
online 13 November 2018.)

INTRODUCTION

Acellular dermal matrices (ADMs) are broadly utilized
as an adjunct to prosthetic breast reconstruction. They offer soft-tissue support to maintain the lateral and inframammary folds and can facilitate a match of the dimensions
of the periprosthetic lamella with the mastectomy skin
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flap envelope.1,2 ADMs are distinguished from one another by their clinical performance, traditionally measured
by complication rates, and by their cost, a factor that will
become even more critical with bundled payment models on the horizon.3–7 The cost of using an ADM not only
includes its price and impact on expensive reconstructive
failures but also its potential for limiting the number of
downstream reconstructive interventions.3,4,8,9 Increased
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initial cost of one product over another may be justifiable
if it increases overall value-based care by improving outcomes and/or limiting future procedures.9
Although a large body of evidence exists evaluating the
safety and complication rates associated with ADM-assisted prosthetic breast reconstruction, there is a surprising
dearth of high quality (level 1 or level 2 evidence) studies, including prospective randomized controlled trials
(RCTs), on the topic. This is a significant limitation that
diminishes the utility of recent meta-analyses on ADM
use in prosthetic breast reconstruction and prevents clinicians from effectively interpreting the results of these
studies without the presence of bias inherent in retrospective study designs.10–12 The BREAST trial, the first RCT to
compare ADMs in submuscular breast reconstruction,
showed that overall complication and implant loss rates
with freeze-dried AlloDerm were comparable with DermaMatrix using a noninferiority design.13–15 A subsequent
RCT comparing ADM slings in submuscular reconstructions failed to demonstrate significant differences in outcomes between AlloDerm RTU and AlloMax. This study,
however, may have been underpowered as complications
rates of 8% versus 26.1% were not found to be significantly different.16 To our knowledge, there are no published
RCTs comparing ADMs to one another when used in prepectoral breast reconstruction, an increasingly popular
technique for prosthetic reconstruction Given the lack of
high-quality studies available, a significant need remains
for carefully designed and adequately powered RCTs comparing outcomes between various ADMs in submuscular
and prepectoral prosthetic breast reconstruction.
Cortiva is a Tutoplast-sterilized human ADM with
similar vascular, collagen, and elastin remodeling characteristics when compared with AlloDerm on histological
analyses.17 To date, there are limited studies comparing
complication rates and outcomes between Cortiva ADM
and AlloDerm ADM. The only existing studies have demonstrated similar complication rates; however, these are
limited by their retrospective study design.18–21 In this
study, we introduce a robust RCT study design to compare
clinical and patient-reported outcomes between Cortiva
ADM and AlloDerm RTU ADM when used as a sling to
support tissue expanders placed in the submuscular location in one study arm, and prepectoral reconstructions
with tissue expanders (TEs) or direct-to-implants (DTI)
in a separate study arm. Furthermore, we present results
from our interim analysis of the submuscular study arm.

METHODS
Study Design

We are conducting a prospective, single-blinded,
randomized control trial comparing AlloDerm RTU
(Allergan Medical, Irvine, Calif.) medium thickness
(1.6 ± 0.4 mm) to Cortiva 1 mm (RTI Surgical, Alachua,
Fla.) Allograft Dermis (1.0 ± 0.2 mm) in the practices of
TMM and MMT. Patients undergoing submuscular breast
reconstruction with a TE and 16 × 8 cm ADM sling consisting of either AlloDerm or Cortiva are compared in one
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study arm. Patients undergoing prepectoral breast reconstruction with either DTI or TE supported by a 20 × 16 cm
ADM sheet are compared in a separate study arm. In both
arms, randomized patients are allocated 1:1 to one ADM
or the other. This study is approved by our institutional
review board (201606168) and listed on clinicaltrials.gov
(NCT02891759).
We began enrolling patients for submuscular reconstruction using an ADM sling in February 2017. We
subsequently noted a significant shift to prepectoral reconstructions both nationally and in our own practices,22,23
and added the prepectoral arm to optimize enrollment
rates and reflect our own pattern of practice. We determined that the perceived and reported differences between prepectoral and submuscular reconstructions like
pain and animation deformity would be too profound,24,25
and create too much variability to be included in the same
analysis and so parallel prepectoral and submuscular arms
were initiated (Fig. 1).
Patient Selection

Female patients, aged 22–70 years old, undergoing immediate prosthetic reconstruction following therapeutic
or prophylactic skin- or nipple-sparing mastectomy with
a body mass index (BMI) less than 36 kg/m2 are enrolled.
We have excluded patients who are pregnant, breastfeeding immediately before mastectomy, unwilling to sign or
unable to comprehend written informed consent. The
decision to proceed with prepectoral or submuscular
reconstruction with either a TE or DTI is determined
preoperatively. Our consent process, however, maintains
flexibility to choose the alternative plane for implant
placement, and device type, if determined clinically appropriate by the plastic surgeon. In those instances, we
would continue to use the ADM to which the patient was
randomized (ie, if the patient was told they would most
likely receive a prepectoral immediate implant and was
randomized to a 20 × 16 cm AlloDerm RTU preoperatively,
but was intraoperatively switched to a submuscular TE,
then the patient would be switched to the submuscular
study arm and would still receive AlloDerm RTU, but a
16 × 8 cm sheet instead).
Surgical Procedure for Submuscular Reconstruction with
Acellular Dermal Matrix Sling

Submuscular reconstructions are performed immediately following a skin- or nipple-sparing mastectomy.
The pectoralis major muscle is elevated by releasing its
caudal attachments to create a submuscular pocket that
accommodates a TE selected based on base width, mastectomy specimen weight, and patient goals. Using absorbable suture, through transverse incisions, the ADM
is secured along the medial, lateral, and inframammary
fold, the TE placed, and the caudal edge of the pectoralis
sutured to the cephalad leading edge of the ADM. For
lateral radial incisions, the ADM is secured medially and
centrally, the TE placed, and ADM inset completed along
the lateral mammary fold. For inframammary incisions,
the ADM is secured to the caudal edge of the pectoralis
and the medial and lateral mammary folds defined be-
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Fig. 1. Flowchart for randomized clinical trial study design including study arm, enrollment numbers,
and outcome metrics.

fore the TE is placed and the ADM secured to define the
inframammary fold.
Surgical Procedure for Prepectoral Reconstructions with
Acellular Dermal Matrix

The ADM is manually fenestrated and tacked superiorly to define the upper pole of the reconstruction after
which the medial and lateral mammary folds are defined
by the ADM with absorbable, tacking sutures. DTIs are
placed if the skin envelopes are deemed adequately perfused by clinical judgment occasionally supplemented
with indocyanine green and laser-assisted imaging. In
these cases, the ADM is draped over the implant with sufficient tension to minimize the risk of malrotation. Otherwise, a TE is placed, tabbed to avoid malposition, with
additional lower pole laxity accounted for with the inset.
The inframammary border of the ADM inset is placed last,
with a gutter to reinforce the integrity of the lower pole
when sufficient ADM is available.
Study Endpoints

Patients undergoing TE placement in either study arm
are followed until exchange with an implant, flap, or both,
or premature device removal for any reason. Patients undergoing DTI reconstruction are followed for at least 3
months postoperatively. Patients undergoing reoperation
of the surgical site without device exchange or removal
are kept in the study. Breast-level data are independently

collected for bilateral cases so if one device is removed or
exchanged prematurely, the patient remains in the study
until the contralateral breast is removed or exchanged for
TEs, or at least 3 months postoperatively for DTIs. Date of
drain removal, which occurs once output drops below 30
cc for 24 hours, is prospectively recorded.
Outcome Measures

The primary outcome measure, analyzed at the
breast-level, is premature explantation of the TE before exchange, or unintended explantation of a DTI
reconstruction before 3 months. Secondary breast-level
outcome measures include other complications like seroma, cellulitis, wound or ADM dehiscence, or skin flap
necrosis. We record TE or DTI device size, absolute and
relative and final TE fill volumes, time to drain removal,
reason for premature explantation, and the type and
timing of final reconstruction upon TE exchange. At the
time of TE removal, the decision to proceed to an implant exchange versus a flap was based on surgeon and
patient preference with a bias toward flaps in radiated
patients. ADM integration is semiquantitatively assessed
at the time of TE exchange or TE or DTI premature removal using a grading scale outlined in Table 5 categorized as 0%, <50%, 50–99%, and 100% ADM integration.
Patient level data include antibiotic use and narcotic
consumption postoperatively. Patient-reported outcomes
are measured with the pre- and postoperative Breast-Q
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for all patients, and Qscore reported as an absolute value
and ΔQscore for domains where pre- and postoperative
values are generated.
Sample Size

Sample size determination was based on the primary
hypothesis test for the incidence of premature TE or DTI
removal. We assumed a premature TE or DTI removal
rate of 20% as observed in one ADM group and 9% in the
other ADM group in patients undergoing prepectoral
reconstruction and in patients undergoing submuscular reconstruction, respectively. The hypothesized rates
are based on published data from our group in >3,000
breasts who have undergone similar procedures.7,26–28 For
this phase 2 randomized control trial, we require 180 eligible patients, per arm, to achieve 80% power based on
the 1-sided Z test with pooled variance to detect a difference between the incidence rates of the 2 ADMs at a
0.1 significance level.29 We will separately compare the
2 ADMs among 180 patients receiving prepectoral and
among 180 patients receiving submuscular reconstruction (Fig. 1).
Statistical Analysis

For the final analysis, we will use logistic regression
models to assess the effect of ADM type accounting for
other confounding factors like obesity, age, radiation therapy, chemotherapy, lymph node surgery, surgery type, and
cancer stage on the presence of complications. Variables
that are significant (P ≤ 0.2) in univariate analysis and/
or clinically relevant will be included in the multivariate
logistic regression model.
Statistical analysis of Breast-Q data will be performed
on 18 scales, derived from 6 modules of the Breast-Q for
breast reconstruction.21 The Breast-Q is scored on a 0–
100 points scale (0-dissatisfied, 100-maximally satisfied)
using QScore, which has been developed according to
the Rasch model.30 The Mann-Whitney U test will be used
to detect the difference in data generated from evaluation of the Breast-Q, TE fills, drain use, and narcotic
use between ADM types. The Gamma regression in the
generalized linear model framework will be applied to
model QScore with incorporation of other confounding
factors.
Chi-square and the Fisher’s exact test were used in the
interim analysis to detect the association between ADM
type and TE or DTI removal incidence and between
ADM type and complications. For the interim analysis,
we use descriptive statistics to describe the central tendency and variation of 3 outcome variables—physical
well-being, satisfaction with information, and satisfaction with plastic surgeon in each arm. Then, we used a
2-sample t test to compare the mean of each outcome
between the 2 ADMs. We also used the nonparametric
Wilcoxon rank-sum statistic to compare the median of
each outcome between the 2 ADMs. Statistical analyses were performed in SAS (Version 9.4, SAS Institute,
Cary, N.C.) while descriptive statistics were analyzed and
graphed in Prism (Version 7.0 for MAC, GraphPad Software, La Jolla, Calif.).
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RESULTS
Patient Demographics and Surgical Details

Thirty-four patients (Table 1), whose 59 breasts were
reconstructed with AlloDerm RTU (n = 17 patients, n = 28
breasts) or Cortiva 1 mm (n = 17 patients, n = 31 breasts)
submuscular TE, completed the interim analysis (Table 2).
Nearly half of the reconstructions were for prophylactic
mastectomy, and there with no statistically significant differences with respect to BMI, race, incidence of radiation
therapy, nipple-sparing mastectomy, bilateral cases, or
chemotherapy. The AlloDerm RTU group (Table 2) was
comprised of a significantly higher proportion of patients
who had never smoked (P = 0.009). Mastectomy specimen
weight, initial TE fill volume, percentage of the TE initially
filled, and final TE fill volume was not significantly different between groups. The initial size of the TE selected was
significantly larger in patients reconstructed with Cortiva
1 mm (P = 0.02).
Drain Removal

In most cases, the 10 French subpectoral drain was
removed after the 15 French prepectoral drain, with removal of the final drain, regardless of size or location, occurring in 17.7 ± 7.0 days for AlloDerm RTU and 17.0 ± 7.6
days for Cortiva 1 mm. No significant differences were detected between cohorts (Table 3).
Table 1. Breast-level Descriptive Statistics of Patients
Enrolled in the Submuscular Tissue Expander with ADM
Sling Cohort
Variable

AlloDerm RTU

Cortiva 1 mm

P

N (breasts)
Stage (%)

28
31
Prophylactic - 46.4 Prophylactic - 48.4
DCIS - 10.7
DCIS - 12.9
IA – 25.0
IA - 19.4
IB - 3.6
IIA - 12.9
IIA - 14.3
IIB - 3.2
IIB - 14.3
IIIA - 3.2
Radiation (%)
0.0
3.2
0.62
Type of mastectomy (%)
60.7
41.9
0.15
 Nipple-sparing
39.3
58.1
 Skin-sparing
DCIS, ductal carcinoma in situ.

Table 2. Patient-level Descriptive Statistics of Patients
Enrolled in the Submuscular Tissue Expander with ADM
Sling Cohort
Variable
N (patients)
Breast cancer diagnosis (%)
Age (y)
Race
White (%)
Black (%)
BMI (kg/m2)
Smoking status
Current smoker
Never smoker
Bilateral cases (%)
Chemotherapy (%)

AlloDerm
RTU

Cortiva
1 mm

17
82.3
51.9 ± 12.1

17
94.1
47.5 ± 10.9

94.4
5.6
26.4 ± 5.2

100
0.0
26.8 ± 3.1

5.8
88.2
64.7
23.5

17.6
47.1
82.3
35.3

P
1.0
0.30
0.27
0.32
0.76
0.30
0.009
0.26
0.23
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Table 3. Summary of Procedure-related Data Reported at Breast Level
Variable
N (breasts)
Mastectomy specimen weight (g)
Tissue expander volume (mL)
Initial fill volume (mL)
Percentage of tissue expander volume initially filled (%)
Final fill volume (mL)
Time to 10 Fr subpectoral drain removal (d)
Time to 15 Fr prepectoral drain removal (d)
Time to final drain removal

AlloDerm
RTU

Cortiva
1 mm

P

28
676.1 ± 383.6
496.4 ± 117.0
164.6 ± 125.0
32.2
481.6 ± 186.9
17.5 ± 7.5
9.8 ± 4.4
17.7 ± 7.0

31
657.5 ± 237.4
554.8 ± 76.7
191.3 ± 95.4
35.6
510.0 ± 153.4
14.7 ± 7.7
11.5 ± 6.1
17.0 ± 7.6

0.15
0.02
0.52
0.39
0.52
0.19
0.22
0.57

Table 4. Summary of Complications Reported at Breast
Level*
Variable
N (breasts)
Seroma N (breasts) (%)
Explantation N (breasts) (%)

AlloDerm
RTU

Cortiva
1 mm

P

28
3 (10.7)
0 (0.0)

31
0 (0.0)
1 (3.2)

0.06
0.35

*There were no explantations due to excess pain or magnetic resonance
imaging.

Complications

Complications are presented in Table 4. A clinically detectable seroma was identified in 10.7% (N = 3) of breasts reconstructed with AlloDerm RTU and 0% with Cortiva 1 mm.
Premature explantation was performed in no (0.0%) breasts
reconstructed with AlloDerm RTU and 1 breast (3.2%) reconstructed with Cortiva 1 mm. The breast associated with
explantation was also the only one affected by postoperative
cellulitis, initially treated with oral doxycycline followed by
intravenous cefazolin before ultimate explantation.
Timing to Second-stage and ADM Integration

Patients underwent planned exchange of TEs for implants or flaps (Table 5) within 145.6 ± 51.6 days in the AlloDerm RTU and 167.0 ± 61.5 days in the Cortiva 1 mm cohorts
(P = 0.27). The majority of patients were exchanged with a
breast implant alone, but 14.3% in the AlloDerm RTU and
26.6% in the Cortiva 1 mm groups (P = 0.25) received an
autologous flap (Table 5). Integration of the ADM to the
mastectomy flap (Table 5), determined by our semiquantitative analysis, was robust in the majority of patients with no
significant difference between groups (P = 0.69).
Narcotic Use and Patient-reported Outcomes

Most patients stopped using narcotics for pain control
within 1 or 2 weeks of the mastectomy with immediate
Table 5. Summary of Second Operation Details
Variable
N (breasts)
Time to second surgery (days)
TE exchanged with implant (%)
TE exchanged with flap (%)
TE exchanged with
flap + implant (%)
Degree of ADM integration*

AlloDerm
RTU

Cortiva
1 mm

28
145.6 ± 51.6
85.7
14.3
0.0

31
167.0 ± 61.5
73.3
21.4
5.2

2.9 ± 0.5

2.8 ± 0.7

Fig. 2. Time to cessation of postoperative narcotics in submuscular
TEs breast reconstructions with an AlloDerm RTU or Cortiva 1 mm
sling.

reconstruction (Fig. 2). There were no significant differences between the AlloDerm RTU and Cortiva 1 mm
cohorts with respect to physical well-being, or satisfaction
with information or plastic surgeon (Table 6).

DISCUSSION

Prosthetic breast reconstruction has benefited from
the use of ADMs to provide soft-tissue support, maintain
device position, and limit the manipulation of autologous tissues. Although abundant data support the use of
ADMs,31–37 several recent meta-analyses confirm the need
for additional level 1 and 2 evidence to establish how one
ADM compares to another and how they are influenced
by patient and therapeutic factors. There are a limited
number of randomized control trials specifically comparing one ADM to another when providing support for submuscular reconstructions,13,14,16 and none, in the context
of prepectoral reconstructions.
The original iteration of this trial excluded prepectoral breast reconstructions to minimize technique- versus
ADM-associated variability. As our study progressed, how-

P
0.27
0.25

0.69

*“0” = 0% integration; “1” = <50% integration; “2” = 51–99% integration; “3”
= 100% integration.”

Table 6. Postoperative Patient-reported Outcomes
Reported as Q-Scores
Variable

AlloDerm
RTU

Cortiva
1mm

P

Physical well-being
Satisfaction with information
Satisfaction with plastic surgeon

30.4 ± 12.0
53.1 ± 9.0
46.1 ± 4.9

30.5 ± 13.4
49.3 ± 10.0
42.8 ± 7.9

0.69
0.35
0.22

5

PRS Global Open • 2018
ever, we noted a growing percentage of reconstructive
breast implants in our practice, and nationally, were being placed prepectoral. Early data on prepectoral reconstructions suggest that they are associated with less pain,25
less impact on range of motion,38 higher initial and subsequent rates of TE fill volumes,25 improved aesthetic
outcomes,23 less capsular contracture following radiotherapy,39,40 and comparable complication rates to submuscular reconstruction.39 That said, the prospective studies
with long-term follow-up required to further delineate
the advantages and indications for prepectoral breast reconstructions are lacking.25,41–43 Therefore, expanding our
study to specifically evaluate the performance of Cortiva
versus AlloDerm RTU in prepectoral reconstruction has
considerable value. Successful and sustainable prepectoral
reconstruction may be even more reliant on the performance of one ADM over another. In addition to providing
lateral and inframammary fold support, ADMs used for
prepectoral reconstruction are relied upon to provide upper pole coverage, and are typically 2 to 2.5 times larger
(increasing surface area that needs to incorporate) and
more expensive.22,23,39 Recognizing the benefit of studying prepectoral reconstructions, but acknowledging the
marked differences with submuscular reconstructions that
would preclude inclusion into the same cohort, we have
added a separate prepectoral study arm comparing AlloDerm RTU to Cortiva 1 mm.
We chose a prospective randomized control trial design to control for population bias, and the numerous
covariates that impact the heterogeneous population of
women seeking immediate prosthetic breast reconstruction. Nonetheless, randomized control trials may possess
unidentified biases that characterize those patients willing
to participate in them, and are subject to patients who are
lost to follow-up. Further, a substantially higher powered
study would make our findings more robust, and along
with longer term follow-up would enable us to study the
impact of these ADMs on capsular contracture rates. Interim analysis of the first 34 patients to complete the submuscular arm of our study identified no statistically significant
findings clearly attributable to the ADM. Moreover, none
of the postoperative patient-reported outcome metrics
evaluated differed based on ADM (Table 6). Notably, the
composition of our study population closely resembled
that of another RCT, the BREASTrial,13 with some important exceptions. The BREASTtrial is skewed to a higher
proportion of patients with stage III or greater cancers,
radiation, and chemotherapy than our study (Tables 2
and 3). Our study, however, is comprised of a high percentage of smokers (Table 2), which reflects the general
population.44 Compared with the BREASTrial, patients in
our study had drains for a shorter period of time (~17 versus 21 days), with fewer explantations (0–3.3% versus 5
to 11.2%). Preliminary data from our RCT also compares
favorably to retrospective data obtained from Keifer et al.18
that compares freeze-dried AlloDerm to Cortiva, albeit
in a more heterogeneous population that included both
TE and DTI reconstructions. The similar clinical performance metrics that we have identified between AlloDerm
RTU and Cortiva may relate, in part, to similar-appearing
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ADM remodeling on gross examination. We found, using a semiquantitative assessment, no obvious differences
in the degree of ADM integration at the time of TE exchange (Table 5). Upon histologic examination, Moyer et
al.17 have also noted similar levels of elastin deposition and
revascularization of AlloDerm and Cortiva following prosthetic breast reconstruction.

CONCLUSIONS

High-quality evidence is needed to compare the performance of various ADMs used in prosthetic breast reconstruction. Prepectoral reconstructions represent a
unique population within prosthetic breast reconstruction and have several notable differences when compared
with submuscular reconstructions. As such, trials comparing ADM performance should separate these patient
cohorts to eliminate the potential bias that plane of prosthesis placement can have on outcome. In this study, we
outline a protocol for a robust RCT to evaluate complications, clinical outcomes, and patient-reported outcomes
in both submuscular and prepectoral prosthetic breast
reconstruction assisted by 2 distinct types of ADM. Interim
analysis of a limited sample of submuscular reconstructions reveals no evidence of inferiority of outcomes in a
comparison of AlloDerm RTU to Cortiva.
Terence M. Myckatyn, MD, FRCSC, FACS
Plastic and Reconstructive Surgery
Division of Plastic & Reconstructive Surgery
Department of Surgery
Washington University School of Medicine
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